By Fineline Cube 
Abbott Laboratories (NYSE: ABT) announced its financial results for the first quarter of 2026, reporting revenue of USD 11.164 billion, a 3.8% increase year-over-year (YOY). Growth was broad-based across its key segments, with the Diagnostics, Established Pharmaceuticals, and Medical Devices businesses all posting gains, while the Nutrition segment declined.
Segment Performance Breakdown
| Segment | Key Highlights |
|---|---|
| Diagnostics | • Cancer diagnostics surged, fueled by Exact Sciences contribution. • Cologuard achieved double-digit growth; new Cancerguard multi-cancer test showed strong initial performance. • Core Laboratory business grew YOY and sequentially, driven by the U.S., Europe, and Latin America. • Rapid & Molecular Diagnostics saw lower demand YOY due to a milder respiratory virus season. |
| Medical Devices | • Electrophysiology, Heart Failure, and Rhythm Management businesses all delivered double-digit growth. • Diabetes Care, powered by its continuous glucose monitoring (CGM) portfolio, grew 7.6%. |
| Established Pharmaceuticals | • Key emerging markets (Latin America, Asia-Pacific, etc.) posted stellar 12.9% reported sales growth, driven by its branded generics portfolio. |
| Nutrition | • Global sales declined due to lower volumes and the impact of pricing actions implemented in Q4 2025. • The company anticipates volume improvement throughout 2026, supported by new product launches. |
Strategic Outlook
Abbott’s Q1 results demonstrate the resilience and diversification of its healthcare portfolio. The strong performance in high-growth areas like cancer diagnostics, cardiac rhythm management, and emerging market pharmaceuticals more than offset the temporary softness in its Nutrition business. The successful integration of Exact Sciences continues to be a major value driver, while its CGM platform remains a key growth engine in the competitive diabetes market.
Management expressed confidence in its full-year outlook, citing a robust pipeline and the expected recovery in its Nutrition segment as new products gain traction.
Forward-Looking Statements
This brief contains forward-looking statements regarding Abbott’s future financial performance and business strategy. Actual results may differ materially due to factors including market competition, regulatory changes, and global economic conditions.-Fineline Info & Tech